Human RAS gene family consists of 3-functional genes named HRAS, NRAS, and KRAS. 1-
3 RAS genes provide instruction through a signaling pathway (eg Ras/MAPK pathway) for …

RAS was identified as a human oncogene in the early 1980s and subsequently found to be
mutated in nearly 30% of all human cancers. More importantly, RAS plays a central role in …

Mutationally activated and oncogenic versions of the ras genes were first identified in human
tumors in 1982. This discovery prompted great interest in the development of anti-Ras …

Ras is one of the most frequently mutated genes in cancer, and it plays a critical role in
driving tumor growth and resistance to therapies. Therefore, for the past decades, Ras has …

Publisher Summary Several recent research observations have rekindled interest in
targeting Ras for cancer treatment. Genome-wide cancer genome studies have revealed …

Single-agent targeting of RAS-mutated cancers using RAF/MEK/ERK or PI3K/AKT pathway
inhibitors is ineffective; blocking one pathway relieves negative feedback control of RTK …

Introduction: Mutations in ras genes that result in constitutive activation of Ras proteins are
key drivers of oncogenesis, but no effective drugs have been developed that target these …

RAS is the most commonly mutated driver of tumorigenesis, seen in about 30% of all cancer
cases. There is a subset of tumors termed RAS-driven cancers in which RAS mutation or …

The Ras pathway is one of the most commonly deregulated pathways in cancer. However
Ras-driven tumors are often refractory to conventional therapies and a clinically effective …

BETHESDA, MARYLAND—A new initiative at the US National Cancer Institute (NCI) hopes
to succeed where many have failed: to target the 'undruggable'oncogene, RAS. Discovered …